Meng Fanling, Tan Shu, Liu Tianbo, Song Hongtao, Lou Ge
Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China.
Department of Pathology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China.
Tumour Biol. 2016 Apr;37(4):4849-55. doi: 10.1007/s13277-015-4319-9. Epub 2015 Nov 2.
Lysosome-associated protein transmembrane 4ß-35 (LAPTM4B-35) is overexpressed in several solid malignancies. This study determines the expression level of LAPTM4B-35 in the cervical cancer during tumor development and progression. The present study investigated the clinicopathological significance of the coexpression of LAPTM4B-35 and VEGF in patients with cervical cancer. Immunohistochemistry was used to evaluate the expression of LAPTM4B-35 and VEGF in 62 cervical intraepithelial neoplasia (CIN) and 226 cervical carcinoma in comparison with 45 normal cervical specimens. The correlation of combined LAPTM4B-35 and VEGF with clinicopathologic characteristics was analyzed using a chi-squared test. Patient survival was determined using Kaplan-Meier method and log-rank test. A Cox regression analysis was performed to determine the prognostic significance of the factors. Combined LAPTM4B-35 and VEGF expression was significantly associated with FIGO stage (P = 0.014), tumor histologic grade (P = 0.033), lymph node metastasis (P = 0.045), and recurrence (P = 0.010). Kaplan-Meier survival analysis showed that patients with cervical cancer expressing both LAPTM4B-35 and VEGF exhibited both poor overall survival (OS) and disease-free survival (DFS) (P = 0.015 and P = 0.016, respectively). Cox analysis demonstrated that combined LAPTM4B-35 and VEGF expression was an independent factor for both OS and DFS (P = 0.015 and P = 0.016, respectively). Overexpression of LAPTM4B-35combined with positive VEGF expression may serve as a new biological marker to predict the prognosis of cervical carcinoma patients.
溶酶体相关蛋白跨膜4β-35（LAPTM4B-35）在多种实体恶性肿瘤中过表达。本研究确定LAPTM4B-35在宫颈癌发生发展过程中的表达水平。本研究探讨LAPTM4B-35与血管内皮生长因子（VEGF）共表达在宫颈癌患者中的临床病理意义。采用免疫组织化学法评估62例宫颈上皮内瘤变（CIN）、226例宫颈癌组织中LAPTM4B-35和VEGF的表达，并与45例正常宫颈标本进行比较。采用卡方检验分析LAPTM4B-35与VEGF联合表达与临床病理特征的相关性。采用Kaplan-Meier法和对数秩检验确定患者生存率。进行Cox回归分析以确定各因素的预后意义。LAPTM4B-35与VEGF联合表达与国际妇产科联盟（FIGO）分期（P = 0.014）、肿瘤组织学分级（P = 0.033）、淋巴结转移（P = 0.045）及复发（P = 0.010）显著相关。Kaplan-Meier生存分析显示，同时表达LAPTM4B-35和VEGF的宫颈癌患者总生存期（OS）和无病生存期（DFS）均较差（分别为P = 0.015和P = 0.016）。Cox分析表明，LAPTM4B-35与VEGF联合表达是OS和DFS的独立因素（分别为P = 0.015和P = 0.016）。LAPTM4B-35过表达联合VEGF阳性表达可能作为预测宫颈癌患者预后的新生物标志物。
